NCT06704009 - NT-101 Topical Ophthalmic Solution in Patients With Wet AMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 11, 2025

Primary Completion Date

September 25, 2025

Study Completion Date

December 24, 2025

Conditions

Wet Age Related Macular DegenerationWet AMD

Interventions

DRUG

NT-101 0.05 mM

Low concentration of NT-101 (0.05 mM)

DRUG

NT-101 0.2 mM

High concentration of NT-101 (0.2 mM)

Trial Locations (4)

RECRUITING

Erie Retina Research, Erie

RECRUITING

Elman Retina Group, Rosedale

RECRUITING

Duke Eye Center, Durham

RECRUITING

Texas Retina Associates, Dallas